Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio is composed of immunology, rare disease, infectious dise... Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Tonix's rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. 더 보기
Mr. Ainsworth brings over two decades of industry and market access experience to Tonix U.S. Food and Drug Administration (FDA) recently assigned a Prescription Drug User Fee Act (PDUFA) goal...
CHATHAM, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of...
Tonix received FDA’s Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast...
FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been granted in the Day 74 Letter TNX-102 SL is a non-opioid...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.213 | 88.3817427386 | 0.241 | 0.583 | 0.2375 | 221056517 | 0.40293172 | CS |
4 | 0.1196 | 35.7655502392 | 0.3344 | 0.583 | 0.216 | 101655031 | 0.34292297 | CS |
12 | 0.3121 | 219.943622269 | 0.1419 | 1.3 | 0.1264 | 131868163 | 0.37785822 | CS |
26 | -0.0936 | -17.0927684441 | 0.5476 | 1.3 | 0.118 | 73743143 | 0.3496716 | CS |
52 | -9.9524 | -95.637300123 | 10.4064 | 12.48 | 0.118 | 38488202 | 0.50544635 | CS |
156 | -45.286 | -99.0074333188 | 45.74 | 958 | 0.118 | 17628128 | 36.79743369 | CS |
260 | -303.546 | -99.8506578947 | 304 | 958 | 0.118 | 17158887 | 97.66987358 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관